Adage Capital Partners Gp, L.L.C. Compass Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$54.6 Billion
Q3 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 11,130,000 shares of CMPX stock, worth $17.7 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

11,130,000

Previous 11,130,000 -0.0%

Holding current value

$17.7 Million

Previous $11.1 Million 84.0%

% of portfolio

0.04%

Previous 0.02%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.2 - $2.29 $1.5 Million - $2.86 Million	1,250,000 Added 12.65%	11,130,000 $22 Million
Q4 2023 Feb 14, 2024	BUY	$1.4 - $1.98 $4.9 Million - $6.93 Million	3,500,000 Added 54.86%	9,880,000 $15.4 Million
Q3 2023 Nov 14, 2023	BUY	$1.87 - $3.25 $243,100 - $422,500	130,000 Added 2.08%	6,380,000 $12.6 Million
Q1 2023 May 15, 2023	BUY	$3.14 - $5.48 $1.49 Million - $2.6 Million	475,200 Added 8.23%	6,250,000 $20.4 Million
Q4 2022 Feb 14, 2023	BUY	$2.55 - $5.41 $2.98 Million - $6.32 Million	1,168,200 Added 25.36%	5,774,800 $29 Million
Q3 2022 Nov 14, 2022	BUY	$1.9 - $3.37 $380,000 - $674,000	200,000 Added 4.54%	4,606,600 $10.5 Million
Q2 2022 Aug 15, 2022	BUY	$1.43 - $3.1 $3.05 Million - $6.6 Million	2,129,600 Added 93.53%	4,406,600 $11.7 Million
Q1 2022 May 16, 2022	BUY	$1.25 - $3.5 $1.1 Million - $3.07 Million	877,000 Added 62.64%	2,277,000 $3.12 Million
Q4 2021 Feb 14, 2022	BUY	$2.88 - $3.98 $4.03 Million - $5.57 Million	1,400,000 New	1,400,000 $4.44 Million

Others Institutions Holding CMPX

# of Institutions

Shares Held

92M

Call Options Held

Put Options Held

View Full List

About Compass Therapeutics, Inc.

Ticker CMPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 101,285,000
Market Cap $161M
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...

More about CMPX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Compass Therapeutics, Inc. Transaction History